KNW
VRTX icon

Kesler Norman & Wride’s Vertex Pharmaceuticals VRTX Stock Holding History

Kesler Norman & Wride’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-538
Closed -$217K – 269
2025
Q3 		$217K Buy
+538
New +$225K 0.04% 214
2025
Q1 		– Sell
-538
Closed -$217K – 230
2024
Q4 		$217K Sell
538
-965
-64% -$447K 0.05% 209
2024
Q3 		$699K Buy
+1,503
New +$722K 0.14% 136

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Kesler Norman & Wride's VRTX Position: Q4 2025 in Review

Kesler Norman & Wride sold out of Vertex Pharmaceuticals (VRTX) in Q4 2025, closing a stake of 538 shares — an estimated $217K sold.

Kesler Norman & Wride first reported a position in VRTX in Q3 2024 and held it in 3 quarters. The position peaked at $699K in Q3 2024. 1,670 funds tracked by Wall St. Rank hold VRTX as of Q4 2025.

  • Kesler Norman & Wride reported no remaining Vertex Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Kesler Norman & Wride sold 538 Vertex Pharmaceuticals shares in Q4 2025, an estimated $217K.
  • Kesler Norman & Wride first reported a position in Vertex Pharmaceuticals in Q3 2024 and held it in 3 quarters.
  • Kesler Norman & Wride's Vertex Pharmaceuticals position peaked at $699K in Q3 2024.
  • 1,670 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2025.

Based on Kesler Norman & Wride's 13F filing for Q4 2025, filed 10 Feb 2026.